IBDEI03V ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1381,1,3,0)
 ;;=3^Poisoning by aminoglycosides, undetermined, sequela
 ;;^UTILITY(U,$J,358.3,1381,1,4,0)
 ;;=4^T36.5X4S
 ;;^UTILITY(U,$J,358.3,1381,2)
 ;;=^5049357
 ;;^UTILITY(U,$J,358.3,1382,0)
 ;;=T45.1X1A^^8^135^31
 ;;^UTILITY(U,$J,358.3,1382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1382,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, init
 ;;^UTILITY(U,$J,358.3,1382,1,4,0)
 ;;=4^T45.1X1A
 ;;^UTILITY(U,$J,358.3,1382,2)
 ;;=^5051014
 ;;^UTILITY(U,$J,358.3,1383,0)
 ;;=T45.1X1D^^8^135^32
 ;;^UTILITY(U,$J,358.3,1383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1383,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, subs
 ;;^UTILITY(U,$J,358.3,1383,1,4,0)
 ;;=4^T45.1X1D
 ;;^UTILITY(U,$J,358.3,1383,2)
 ;;=^5051015
 ;;^UTILITY(U,$J,358.3,1384,0)
 ;;=T45.1X1S^^8^135^33
 ;;^UTILITY(U,$J,358.3,1384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1384,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, sequela
 ;;^UTILITY(U,$J,358.3,1384,1,4,0)
 ;;=4^T45.1X1S
 ;;^UTILITY(U,$J,358.3,1384,2)
 ;;=^5051016
 ;;^UTILITY(U,$J,358.3,1385,0)
 ;;=T45.1X3A^^8^135^34
 ;;^UTILITY(U,$J,358.3,1385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1385,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, init
 ;;^UTILITY(U,$J,358.3,1385,1,4,0)
 ;;=4^T45.1X3A
 ;;^UTILITY(U,$J,358.3,1385,2)
 ;;=^5051020
 ;;^UTILITY(U,$J,358.3,1386,0)
 ;;=T45.1X3D^^8^135^35
 ;;^UTILITY(U,$J,358.3,1386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1386,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, subs
 ;;^UTILITY(U,$J,358.3,1386,1,4,0)
 ;;=4^T45.1X3D
 ;;^UTILITY(U,$J,358.3,1386,2)
 ;;=^5051021
 ;;^UTILITY(U,$J,358.3,1387,0)
 ;;=T45.1X3S^^8^135^36
 ;;^UTILITY(U,$J,358.3,1387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1387,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, sequela
 ;;^UTILITY(U,$J,358.3,1387,1,4,0)
 ;;=4^T45.1X3S
 ;;^UTILITY(U,$J,358.3,1387,2)
 ;;=^5051022
 ;;^UTILITY(U,$J,358.3,1388,0)
 ;;=T45.1X2A^^8^135^37
 ;;^UTILITY(U,$J,358.3,1388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1388,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, self-harm, init
 ;;^UTILITY(U,$J,358.3,1388,1,4,0)
 ;;=4^T45.1X2A
 ;;^UTILITY(U,$J,358.3,1388,2)
 ;;=^5051017
 ;;^UTILITY(U,$J,358.3,1389,0)
 ;;=T45.1X2D^^8^135^38
 ;;^UTILITY(U,$J,358.3,1389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1389,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, self-harm, subs
 ;;^UTILITY(U,$J,358.3,1389,1,4,0)
 ;;=4^T45.1X2D
 ;;^UTILITY(U,$J,358.3,1389,2)
 ;;=^5051018
 ;;^UTILITY(U,$J,358.3,1390,0)
 ;;=T45.1X2S^^8^135^18
 ;;^UTILITY(U,$J,358.3,1390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1390,1,3,0)
 ;;=3^Poisn by antineopl and immunosup drugs, self-harm, sequela
 ;;^UTILITY(U,$J,358.3,1390,1,4,0)
 ;;=4^T45.1X2S
 ;;^UTILITY(U,$J,358.3,1390,2)
 ;;=^5051019
 ;;^UTILITY(U,$J,358.3,1391,0)
 ;;=T45.1X4A^^8^135^39
 ;;^UTILITY(U,$J,358.3,1391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1391,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, undet, init
 ;;^UTILITY(U,$J,358.3,1391,1,4,0)
 ;;=4^T45.1X4A
 ;;^UTILITY(U,$J,358.3,1391,2)
 ;;=^5051023
 ;;^UTILITY(U,$J,358.3,1392,0)
 ;;=T45.1X4D^^8^135^40
 ;;^UTILITY(U,$J,358.3,1392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1392,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, undet, subs
 ;;^UTILITY(U,$J,358.3,1392,1,4,0)
 ;;=4^T45.1X4D
 ;;^UTILITY(U,$J,358.3,1392,2)
 ;;=^5051024
 ;;^UTILITY(U,$J,358.3,1393,0)
 ;;=T45.1X4S^^8^135^41
